True or false? Diabetes increases the risk for conjunctivitis. Follow the link to see if you got it right!

Which new drug class have you seen the best results with in lowering A1c’s? 1) DPP-4 2) GLP-4 3) SGLT-2 4) Other Follow the link to see what others think!

Manage diabetes quickly and on the go with LogFrog DB Lite, free for seven days of use! In a few seconds you can track: blood glucose, insulin or oral medication, carb intake, exercise, weight and more! LogFrog DB Lite can help keep you organized and help you analyze and better understand your data.

There are a lot of prescribers who are mixing DPP-4 inhibitors and SGLT-2 inhibitors to manage glucose levels.The recent research showing the value of SGLT-2 inhibitors on cardiovascular outcomes has led this addition to the diabetes mix, especially since cardiovascular disease is greatly increased in diabetes patients. This week, we …

The DPP-IV inhibitor sitagliptin was safe and effective over 3 years for adults aged at least 75 years who had well-controlled type 2 diabetes and cardiovascular disease, findings from an analysis of TECOS study data show.

We know from previous studies that obesity and type 2 diabetes are associated with vascular stiffening and the development of cardiovascular disease.

A DPP-4 inhibitor can help to prevent kidney function and did not have any negative cardiovascular effects.

When we explain to a patient how insulin release occurs, we often oversimplify it. We tell them that the release is caused by signals sent to the beta cells when food enters our body. We often add in the “simplicity” of, if you eat the right foods your pancreas will …

When we think about disasters, we usually think of the outcome, a poor health outcome. We don’t always think about the journey. The journey to poor health outcomes are many. Today I am reminded of not having the insurance coverage for the correct medication. Without it, one can have a disaster, poor diabetes management. The consequences of that, as well as the disruption to running a smooth office.

Dr. Altamash Shaikh talks with Diabetes in Control Associate Medical Editor Joy Pape at the 2016 AACE Meeting. In part 2 of this Exclusive Interview, Dr. Shaik explains the pervasiveness of diabetes among the younger Indian population and the three reasons for this occurrence.